Comprehensive mapping of immune perturbations associated with severe COVID-19
Open accessThe DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Abstract
Profound plasmablast expansion, innate cell modulation, and T cell activation are defining features of severe COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We believe that the features described herein may help to identify the immunopathology of similar illnesses, such as irAEs and CRS due to other immunotherapies (e.g. checkpoint inhibitors, CAR-T-cells) or COVID-19 [4, 18, 19], and to inform discussions on the type and length of clinical and immune monitoring warranted in such patients.”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical–pathologic correlation in these individuals resulted in valuable observations that may be instructive in understanding mechanisms of immune-induced pathologies, including those of checkpoint inhibitors, CAR-T cells, and infections such as COVID-19, known to target mucosal tissues and cause severe CRS [1, 5, 8, 18, 19].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“suggesting the lung as a source for the elevated plasma levels of type I IFNs early on infection”
From COVID-19 and the human innate immune system (2021) · cites this paper as Kuri-Cervantes et al., 2020
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ineffective IFN innate immunity has been strongly associated with failure to control a primary SARS-CoV-2 infection and a high risk of fatal COVID-19, accompanied by innate cell immunopathology and a plasma cytokine signature of elevated CXCL10, interleukin (IL)-6, and IL-8 in many studies (Aid et al., 2020; Kuri-Cervantes et al., 2020; Li et al., 2020b; Lucas et al., 2020; Radermecker et al., 202”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Kuri-Cervantes et al., 2020
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“particularly observation of elevated frequencies of neutrophils (the most common cell type of the innate immune system) in blood (Kuri-Cervantes et al., 2020), and massive numbers of neutrophils in lungs, associated with severe, end-stage COVID-19 disease (Li et al., 2020b; Liao et al., 2020; Radermecker et al., 2020; Schurink et al., 2020). In contrast, end-stage disease is not generally”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Kuri-Cervantes et al., 2020
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Wang, X., Xu, W., Hu, G., Xia, S., Sun, Z., Liu, Z., Xie, Y., Zhang, R., Jiang, S., & Lu, L. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0498-4 · Cited by 175
RetractedWang, X., Xu, W., Hu, G., Xia, S., Sun, Z., Liu, Z., Xie, Y., Zhang, R., Jiang, S., & Lu, L. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0424-9 · Cited by 161
RetractedClinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Martínez–González, M. B. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,296
Binary Codes capable of currecting deletions, insertions, and reversals
Levenshtein, V. I. (1965) · Soviet physics. Doklady · Cited by 14,807
Chen, Y., Wang, L., Kang, Q., Zhang, X., Yu, G., Wan, X., Wang, J., & Zhu, K. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000477308 · Cited by 10,679
Research works printed but not linked: 2
- WHO Novel Coronavirus 2019 Reports (World Health Organization 2020) vol. 2020.
- 10.1146/annurev.iy.13.040195.001015 · doi:10.1146/annurev.iy.13.040195.001015 · Paper page
Cited by
Items 401–500 of 761
Boulanger, M. C., Molina, E., Wang, K., Kickler, T. S., Xu, Y., & Garibaldi, B. T. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.01.040 · Cited by 15
Immune response pattern across the asymptomatic, symptomatic and convalescent periods of COVID-19
Chen, Y., Zhang, N., Zhang, J., Guo, J., Dong, S., Sun, H., Gao, S., Zhou, T., Li, M., Liu, X., et al. (2021) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2021.140736 · Cited by 16
Golshani, M., & Hrdý, J. (2022) · Vaccines · doi:10.3390/vaccines10020279 · Cited by 15
Khare, K., & Pandey, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.973070 · Cited by 16
Jeong, H., Lee, J. S., Ko, J., Hong, S., Oh, S. T., Choi, S., Peck, K. R., Yang, J. H., Chung, S. H., Kim, S., et al. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00964-8 · Cited by 17
The CXCR6/CXCL16 axis links inflamm-aging to disease severity in COVID-19 patientsPreprint
Payne, D., Dalal, S., Leach, R., Parker, R., Griffin, S. D. C., McKimmie, C. S., Cook, G. P., Richards, S. J., Hillmen, P., Munir, T., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.25.428125 · Cited by 15
de Mattos Barbosa, M. G., Liu, H., Huynh, D., Shelley, G., Keller, E. T., Emmer, B. T., Sherman, E., Ginsburg, D., Kennedy, A. A., Tai, A. W., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.147386 · Cited by 14
Self-citationLin, Q. X. X., Rajagopalan, D., Gamage, A. M., Tan, L. M., Venkatesh, P. N., Chan, W. O. Y., Kumar, D., Agrawal, R., Chen, Y., Fong, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44524-0 · Cited by 17
Toscano, E., Martínez‐Gallo, M., Arrese-Muñoz, I., Giné, A., Troyano, N. D., Gabriel-Medina, P., Riveiro‐Barciela, M., Labrador‐Horrillo, M., Martínez‐Valle, F., Sánchez‐Montalvá, A., et al. (2021) · BMC Medicine · doi:10.1186/s12916-022-02345-w · Cited by 15
Elevated ubiquitination contributes to protective immunity against severe SARS‐CoV‐2 infection
Che, Y., Jiang, D., Zhang, Y., Zhang, J., Xu, T., Sun, Y., Fan, J., Wang, J., Chang, N., Wu, Y., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1103 · Cited by 15
Ruytinx, P., Vandormael, P., Fraussen, J., Pieters, Z., Thonissen, S., Hellings, N., Stinissen, P., Callebaut, I., Penders, J., Vanhove, K., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-46421-4 · Cited by 14
Endothelial cell, myeloid, and adaptive immune responses in SARS‐CoV‐2 infection
Degauque, N., Haziot, A., Brouard, S., & Mooney, N. (2021) · The FASEB Journal · doi:10.1096/fj.202100024r · Cited by 14
Altered Blood Cell Traits Underlie a Major Genetic Locus of Severe COVID-19
Zhou, J., Sun, Y., Huang, W., & Ye, K. (2021) · The Journals of Gerontology Series A · doi:10.1093/gerona/glab035 · Cited by 14
Discrete Immune Response Signature to SARS-CoV-2 mRNA Vaccination Versus InfectionPreprint
Ivanova, E. N., Devlin, J. C., Buus, T. B., Koide, A., Cornelius, A. R., Samanovic, M. I., Herrera, A. M., Zhang, C., Desvignes, L., Ødum, N., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3838993 · Cited by 14
Zhang, Y., Shi, F., Wang, Y., Meng, Y., Zhang, Q., Wang, K., Zeng, P., & Diao, H. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.835590 · Cited by 14
Rodríguez‐Ubreva, J., Calafell-Segura, J., Calvillo, C. L., Keller, B., Ciudad, L., Handfield, L., de la Calle‐Fabregat, C., Godoy‐Tena, G., Andrés‐León, E., Hoo, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54732-x · Cited by 15
Ghimire, R., Shrestha, R., Amaradhi, R., Patton, T., Whitley, C., Chanda, D., Liu, L., Ganesh, T., More, S., & Channappanavar, R. (2025) · Journal of Virology · doi:10.1128/jvi.01668-24 · Cited by 14
Scott, J. K., & Breden, F. J. (2020) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2020.10.001 · Cited by 13
Illuminating the immunopathology of SARS‐CoV ‐2
Saksena, S., & Chattopadhyay, P. K. (2021) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21988 · Cited by 14
Gao, Y., Chen, L., Chi, J., Zeng, S., Feng, X., Li, H., Liu, D., Feng, X., Wang, S., Wang, Y., et al. (2021) · Journal of Intensive Care · doi:10.1186/s40560-021-00531-1 · Cited by 14
Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies
Rawat, P., Sharma, D., Srivastava, A., Vani, J., & Gromiha, M. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-89621-6 · Cited by 13
Kang, C. K., Shin, H., Park, W., & Kim, H. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-022-00857-2 · Cited by 10
Dysregulation of the leukocyte signaling landscape during acute COVID-19
Turnbull, I. R., Fuchs, A. G., Remy, K. E., Kelly, M. P., Frazier, E. P., Ghosh, S., Chang, S.-W., Mazer, M. B., Hess, A., Leonard, J. M., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264979 · Cited by 14
T-Cell Repertoire Characteristics of Asymptomatic and Re-Detectable Positive COVID-19 Patients
Li, Y., Hu, J., Wang, Y., Liu, D., Shi, Y., Zhang, J., Liu, Y., Lin, D., Lin, J., Hu, W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.769442 · Cited by 15
Landscape of infection enhancing antibodies in COVID-19 and healthy donors
Ismanto, H. S., Xu, Z., Saputri, D. S., Wilamowski, J., Li, S., Nugraha, D. K., Horiguchi, Y., Okada, M., Arase, H., & Standley, D. M. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.11.001 · Cited by 14
Belkacem, I. A., García, C. C., Millet-Wallisky, E., Izquierdo, N., Loosveld, M., Arnoux, I., Morange, P., Galland, F., Lambert, N. C., Malergue, F., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-25259-2 · Cited by 14
Lung T cell response in COVID-19
Shakiba, M. H., Gemünd, I. D., Beyer, M., & Bonaguro, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1108716 · Cited by 15
Jędrzejewska, A., Kawecka, A., Braczko, A., Romanowska‐Kocejko, M., Stawarska, K., Deptuła, M., Zawrzykraj, M., Frańczak, M., Król, O., Harasim, G., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713140 · Cited by 15
Tsukalov, I., Sánchez‐Cerrillo, I., Rajas, O., Ávalos, E., Iturricastillo, G., Esparcia, L., Buzón, M. J., Genescà, M., Scagnetti, C., Popova, O., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46322-8 · Cited by 16
Koeppen, M., Rosenberger, P., & Magunia, H. (2021) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.1177/1179548421992327 · Cited by 13
Li, Z., Gao, Q., Ren, Z., Zhou, H., Qian, Z., & Peng, J. (2021) · Biomarkers in Medicine · doi:10.2217/bmm-2021-0085 · Cited by 13
Lima, E. N. D. C., Octaviano, A. L. M., Piqueira, J. R. C., Diaz, R. S., & Justo, J. F. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s341890 · Cited by 13
Innate Immune Cytokine Profiling and Biomarker Identification for Outcome in Dengue Patients
Pradeep, S. P., Venkatesh, P. H., Manchala, N. R., Veedu, A. V., Basavaraju, R. K., Selvasundari, L., Ramakrishna, M., Chandrakiran, Y., Krishnamurthy, V., Holigi, S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.677874 · Cited by 14
Siles, N., Schuler, M., Maguire, C. P., Amengor, D., Nguyen, A. W., Wilen, R. E., Rogers, J. E., Bazzi, S. A., Caslin, B., DiPasquale, C., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00828-4 · Cited by 12
Tuberculosis Trends in the Post‐COVID‐19 Era: Is It Going to be a Global Concern?
Khojasteh‐Kaffash, S., Habibzadeh, A., Moghaddam, S., Afra, F., Samieefar, N., & Fateh, A. (2025) · Health Science Reports · doi:10.1002/hsr2.70792 · Cited by 16
Fischer, B., Lindenkamp, C., Lichtenberg, C., Birschmann, I., Knabbe, C., & Hendig, D. (2021) · Life · doi:10.3390/life11080805 · Cited by 12
Daix, T., Jeannet, R., Padilla, A. C. H., Vignon, P., Feuillard, J., & François, B. (2021) · Journal of Intensive Care · doi:10.1186/s40560-021-00575-3 · Cited by 12
Chronic Inflammation Might Protect Hemodialysis Patients From Severe COVID-19
Prietl, B., Odler, B., Kirsch, A. H., Artinger, K., Eigner, M., Schmaldienst, S., Pfeifer, V., Stanzer, S., Eberl, A., Raml, R., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.821818 · Cited by 12
Papanikolaou, C., Rapti, V., Stellas, D., Stefanou, D. T., Syrigos, K., Pavlakis, G. N., & Souliotis, V. L. (2022) · Vaccines · doi:10.3390/vaccines10101764 · Cited by 13
Zhang, L., Zhang, Y., Wang, R., Liu, X., Zhao, J., Tsuda, M., & Li, Y. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1035711 · Cited by 12
Laub, O., Leipold, G., Toncheva, A. A., Peterhoff, D., Einhauser, S., Neckermann, P., Borchers, N. S., Santos-Valente, E., Kheiroddin, P., Buntrock‐Döpke, H., et al. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.678937 · Cited by 16
Xu, A. M., Li, D., Ebinger, J. E., Mengesha, E., Elyanow, R., Gittelman, R., Chapman, H., Joung, S. Y., Botwin, G. J., Pozdnyakova, V., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.880190 · Cited by 12
Comprehensive mapping of immune perturbations associated with aplastic anemia
Wang, H., Chen, Y., Deng, H., Zhang, J., Jiang, X., Mo, W., Wang, S., Zhou, R., & Liu, Y. (2024) · Cell Biology and Toxicology · doi:10.1007/s10565-024-09914-0 · Cited by 11
Adaptive immune responses to SARS-CoV-2
Forthal, D. N. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.009 · Cited by 13
Signatures of B Cell Receptor Repertoire Following Pneumocystis Infection
Sun, H., Yang, H., Zhai, K., & Tong, Z.-H. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.636250 · Cited by 16
An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19
Soleimanian, S., Alyasin, S. S., Sepahi, N., Ghahramani, Z., Kanannejad, Z., Yaghobi, R., & Karimi, M. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.884879 · Cited by 13
Pathogenic Mechanism and Multi-omics Analysis of Oral Manifestations in COVID-19
Hao, M., Wang, D., Xia, Q., Kan, S., Chang, L., Liu, H., Yang, Z., & Liu, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.879792 · Cited by 11
Chaudhary, J. K., Saini, D., Chaudhary, P. K., Maurya, A., Verma, G. K., Gupta, A. K., Roshan, R., Vats, T. K., Garg, N., Yadav, D., et al. (2022) · Cells · doi:10.3390/cells11142175 · Cited by 12
The dynamics of γδ T cell responses in nonhuman primates during SARS-CoV-2 infection
Fears, A. C., Walker, E. M., Chirichella, N. R., Slisarenko, N., Merino, K. M., Golden, N., Picou, B., Spencer, S., Russell‐Lodrigue, K., Doyle‐Meyers, L. A., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-04310-y · Cited by 12
A possible increased risk of metamizole‐associated neutropenia among COVID‐19 patients
Lerman, T. T., Sagi, M., Shafir, Y., Sheena, L., Cohen, E., Goldberg, E., & Krause, I. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14703 · Cited by 12
Overholt, K. J., Krog, J., Zanoni, I., & Bryson, B. D. (2021) · iScience · doi:10.1016/j.isci.2021.102738 · Cited by 11
Liu, Y., Wu, Y., Liu, B., Zhang, Y., San, D., Chen, Y., Zhou, Y., Yu, L., Zeng, H., Zhou, Y., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.677025 · Cited by 13
Role of the cellular immunity in the formation of the immune response in coronavirus infections
Ia, I., Omelchenko, N. D., Filippenko, A. V., Trufanova, A. A., & Носков, А. К. (2021) · Medical Immunology (Russia) · doi:10.15789/1563-0625-rot-2302 · Cited by 12
Forte, D., Pellegrino, R. M., Trabanelli, S., Tonetti, T., Ricci, F., Cenerenti, M., Comai, G., Tazzari, P. L., Lazzarotto, T., Buratta, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1085610 · Cited by 12
Naiditch, H., Betts, M. R., Larman, H. B., Levi, M., & Rosenberg, A. Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1376654 · Cited by 10
Self-citationSánchez‐Conde, M., Vizcarra, P., Pérez-García, J. M., Gión, M., Martialay, M. P., Taboada, J., Alonso-Fernández, A., Sampayo-Cordero, M., Malfettone, A., Tena, I., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.08.007 · Cited by 10
Shete, A., Deshpande, S., Sawant, J., Warthe, N., Thakar, M. R., Madkaikar, M. R., Pradhan, V., Rao, P., Rohatgi, S. J., Mukherjee, A., et al. (2023) · Immunobiology · doi:10.1016/j.imbio.2023.152384 · Cited by 10
Kang, Y., Lu, S., Zhong, R., You, J., Chen, J., Li, L., Huang, R., Xie, Y., Chen, F., Chen, J., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23583 · Cited by 10
Sun, Z., Zhang, Z., Banu, K., Azzi, Y. A., Reghuvaran, A. C., Fredericks, S., Planoutene, M., Hartzell, S., Kim, Y., Pell, J. F., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2022010125 · Cited by 11
Patiño-Aldana, A. F., Ruiz-Sternberg, Á. M., Pinzón-Rondón, Á. M., Molano‐González, N., & Lima, D. R. R. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s371067 · Cited by 10
Pan, T., Cao, G., Tang, E., Zhao, Y., Penaloza‐MacMaster, P., Fang, Y. H., & Huang, J. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1105673 · Cited by 10
Brunk, F., Moritz, A., Nelde, A., Bilich, T., Casadei, N., Fraschka, S. A. K., Heitmann, J. S., Hörber, S., Peter, A., Rammensee, H., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202149290 · Cited by 10
Tembhare, P. R., Sriram, H., Chatterjee, G., Khanka, T., Gokarn, A. G., Mirgh, S. P., Rajendra, A., Chaturvedi, A., Ghogale, S., Deshpande, N., et al. (2021) · Immunology and Cell Biology · doi:10.1111/imcb.12504 · Cited by 10
Neuraminidase inhibitors rewire neutrophil function in vivo in murine sepsis and ex vivo in COVID-19Preprint
Formiga, R. D. O., AMARAL, F. C., Souza, C. F., Mendes, D. A. G. B., Wanderley, C. W. S., Lorenzini, C. B., Santos, A. A., Antônia, J., Faria, L. F., Natale, C. C., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.12.379115 · Cited by 14
Kilpeläinen, A., Jiménez‐Moyano, E., Blanch-Lombarte, O., Ouchi, D., Peña, R., Quirant‐Sánchez, B., Pérez‐Caballero, R., Chamorro, A., Blanco, I., Martínez-Cáceres, E. M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.815041 · Cited by 9
McCarthy, E. E., Odorizzi, P. M., Lutz, E., Smullin, C. P., Tenvooren, I., Stone, M., Simmons, G., Hunt, P. W., Feeney, M. E., Norris, P. J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110815 · Cited by 9
Al‐Attiyah, R., Safar, H. A., Botras, L., Botras, M., Al-Kandari, F., Chehadeh, W., & Mustafa, A. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.851765 · Cited by 10
COVID-19 vs. Cancer Immunosurveillance: A Game of Thrones within an Inflamed Microenviroment
Liapis, I., & Baritaki, S. (2022) · Cancers · doi:10.3390/cancers14174330 · Cited by 9
Cellular pathways and molecular events that shape autoantibody production in COVID-19
Tsay, G. J., & Zouali, M. (2024) · Journal of Autoimmunity · doi:10.1016/j.jaut.2024.103276 · Cited by 9
Kaushik, A., Chang, I., Han, X., He, Z., Komlósi, Z. I., Ji, X., Cao, S., Akdiş, C. A., Boyd, S. D., Pulendran, B., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1374828 · Cited by 9
Current treatment of Psoriasis triggered by Cytokine Storm and future immunomodulation strategies
Braga, G. D. C., Francisco, G. R., & Bagatini, M. D. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02481-1 · Cited by 10
Eosinophils and COVID‐19: Insights into immune complexity and vaccine safety
Sahli, W., Vitte, J., & Desnues, B. (2025) · Clinical and Translational Allergy · doi:10.1002/clt2.70050 · Cited by 13
Nehar-Belaid, D., Mejías, A., Xu, Z., Marcheş, R., Yerrabelli, R., Guo, C., Mertz, S. E., Ye, F., Sánchez, P. J., Tsang, J. S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59411-z · Cited by 11
Maggi, E., Azzarone, B. G., Canonica, G. W., & Moretta, L. (2021) · Allergy · doi:10.1111/all.15112 · Cited by 9
Lymphocyte Population Changes at Two Time Points during the Acute Period of COVID-19 Infection
Scalia, G., Raia, M., Gelzo, M., Cacciapuoti, S., Rosa, A. D., Pinchera, B., Scotto, R., Tripodi, L., Mormile, M., Fabbrocini, G., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154306 · Cited by 9
Yi, J., Miao, J., Zuo, Q., Owusu, F., Dong, Q., Lin, P., Wang, Q., Gao, R., Kong, X., & Yang, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.978619 · Cited by 11
Zhao, J., Zhu, J., Huang, C., Zhu, X., Zhu, Z., Wu, Q., & Yuan, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1035151 · Cited by 9
Features of HLA class I expression and its clinical relevance in SARS‐CoV‐2: What do we know so far?
Bouayad, A. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2236 · Cited by 9
Zanchettin, A. C., Barbosa, L. V., Dutra, A. A., Prá, D. M. M., Pereira, M. R. C., Stocco, R. B., Martins, A. P. C., de Paula, C. B. V., Nagashima, S., de Noronha, L., et al. (2022) · Viruses · doi:10.3390/v14081699 · Cited by 10
Abdollahi, N., Jeusset, L., de Septenville, A. L., Ripoche, H., Davi, F., & Bernardes, J. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010411 · Cited by 11
Bengsch, B., Schwabenland, M., Salié, H., Tanevski, J., Killmer, S., Matschke, J., Püschel, K., Mei, H. E., Boettler, T., Neumann‐Haefelin, C., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-63687/v1 · Cited by 9
Niedźwiedzka‐Rystwej, P., Grywalska, E., Hrynkiewicz, R., Bębnowska, D., Wołącewicz, M., Majchrzak, A., & Parczewski, M. (2021) · Cells · doi:10.3390/cells10071817 · Cited by 10
Li, X., Zhang, Y., He, L., Si, J., Qiu, S., He, Y., Wei, J., Wang, Z., Xie, L., Li, Y., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.66369 · Cited by 8
Odak, I., Schultze-Florey, C. R., Hammerschmidt, S. I., Ritter, C., Willenzon, S., Friedrichsen, M., Ravens, I., Sikora, R., Bayir, L. M., Jauregui, R. G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.863039 · Cited by 8
Wang, Z., Zhan, J., & Gao, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1015271 · Cited by 8
Relationship between Vitamin D and Immunity in Older People with COVID-19
Lauretani, F., Salvi, M., Zucchini, I., Testa, C., Cattabiani, C., Arisi, A., & Maggio, M. G. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20085432 · Cited by 9
Kim, I. S., Kang, C. K., Lee, S. J., Lee, C., Kim, M., Seo, C., Kim, G., Lee, S., Park, K. S., Chang, E., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29199 · Cited by 8
Developmental Impacts of Epigenetics and Metabolism in COVID-19
Naik, N. C., Patel, M., & Sen, R. (2024) · Journal of Developmental Biology · doi:10.3390/jdb12010009 · Cited by 8
Developing CAR-immune cell therapy against SARS-CoV-2: Current status, challenges and prospects
Chen, Y., Liu, C., Fang, Y., Chen, W., Qiu, J., Zhu, M., Wei, W., & Tu, J. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116066 · Cited by 9
Zurochka, A. V., Dobrynina, M. A., Сафронова, Э. А., Александрович, З. В., Zuikova, A. A., Петрович, С. Г., Забков, О. И., Mosunov, A. A., Verkhovskaya, M. D., Ducardt, V. V., et al. (2024) · Russian Journal of Infection and Immunity · doi:10.15789/2220-7619-ait-17646 · Cited by 8
Prothrombotic antibodies targeting the spike protein's receptor-binding domain in severe COVID-19
Zhu, W., Zheng, Y., Yu, M., Witman, N. D., Zhou, L., Wei, J., Zhang, Y., Topchyan, P., Nguyen, C. P., Wang, D., et al. (2024) · Blood · doi:10.1182/blood.2024025010 · Cited by 9
HMGB1: A Potential Target of Nervus Vagus Stimulation in Pediatric SARS-CoV-2-Induced ALI/ARDS
Jankauskaitė, L., Malinauskas, M., & Mickeviciute, G. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.884539 · Cited by 8
Gazzinelli-Guimarães, P. H., Sanku, G., Sette, A., Weiskopf, D., Schaughency, P., Lack, J., & Nutman, T. B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.883159 · Cited by 9
In vitro high-content tissue models to address precision medicine challenges
Afewerki, S., Stocco, T. D., Silva, A. D. R., Furtado, A. S. A., de Sousa, G. F., Ruiz‐Esparza, G. U., Webster, T. J., Marciano, F. R., Strømme, M., Zhang, Y. S., et al. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101108 · Cited by 9
Functionality of immune cells in COVID-19 infection: development of cell-based therapeutics
Sayahinouri, M., Firouz, S. M., Sadrabadi, A. E., Masoudnia, M., Abdolahi, M., Jafarzadeh, F., Nouripour, M., Mirzazadeh, S., Zangeneh, N., Jalili, A., et al. (2023) · Bioimpacts · doi:10.34172/bi.2023.23839 · Cited by 14
COVID-19-Omics Report: From Individual Omics Approaches to Precision Medicine
Louis, I. V.-S., Fang, D., Amer, Y., & Mohei, H. (2023) · Reports — Medical Cases Images and Videos · doi:10.3390/reports6040045 · Cited by 8
High-dimensional phenotyping of the peripheral immune response in community-acquired pneumonia
Reijnders, T. D. Y., Schuurman, A. R., Verhoeff, J., van den Braber, M., Douma, R. A., Faber, D. R., Paul, A., Wiersinga, W. J., Saris, A., García-Vallejo, J. J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1260283 · Cited by 8
Çevirgel, A., Vos, M. W., Holtrop, A. F., Beckers, L., Reukers, D. F. M., Meijer, A., Rots, N. Y., van Beek, J., van Baarle, D., & de Wit, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-55148-9 · Cited by 8
Oommen, A. M., Cunningham, S., & Joshi, L. (2021) · Viruses · doi:10.3390/v13010082 · Cited by 10
Emadi‐Baygi, M., Ehsanifard, M., Afrashtehpour, N., Norouzi, M., & Joz-Abbasalian, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.778913 · Cited by 11
Metadata
- Authors
- Kuri-Cervantes, L., Pampena, M. B., Meng, W., Rosenfeld, A. M., Ittner, C. A. G., Weisman, A. R., Agyekum, R. S., Mathew, D., Baxter, A. E., Vella, L. A., Kuthuru, O., Apostolidis, S. A., Bershaw, L., Dougherty, J., Greenplate, A. R., Pattekar, A., Kim, J., Han, N., Gouma, S., Weirick, M. E., Arevalo, C. P., Bolton, M. J., Goodwin, E. C., Anderson, E. M., Hensley, S. E., Jones, T. K., Mangalmurti, N. S., Luning Prak, E. T., Wherry, E. J., Meyer, N. J., & Betts, M. R.
- Affiliations
- University of Pennsylvania (US)
- Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, Philadelphia, PA 19104, USA.
- Children's Hospital of Philadelphia (US)
- Hospital of the University of Pennsylvania (US)
- Parker Institute for Cancer Immunotherapy (US)
- Corresponding author
- Kuri-Cervantes, Leticia
- Wherry, E. John
- Meyer, Nuala J.
- Betts, Michael R.
- ORCID
- Kuri-Cervantes, Leticia
- Pampena, Maria Betina
- Meng, Wenzhao
- Rosenfeld, Aaron M.
- Weisman, Ariel R.
- Agyekum, Roseline S.
- Mathew, Divij
- Baxter, Amy E.
- Vella, Laura A.
- Kuthuru, Oliva
- Apostolidis, Sokratis A.
- Bershaw, Luanne
- Dougherty, Jeanette
- Greenplate, Allison R.
- Pattekar, Ajinkya
- Kim, Justin
- Han, Nicholas
- Gouma, Sigrid
- Weirick, Madison E.
- Arevalo, Claudia P.
- Bolton, Marcus J.
- Anderson, Elizabeth M.
- Hensley, Scott E.
- Jones, Tiffanie K.
- Mangalmurti, Nilam S.
- Luning Prak, Eline T.
- Wherry, E. John
- Meyer, Nuala J.
- Betts, Michael R.
- Venue
- Science Immunology
- Published
- 2020-07-03
- Volume
- 5
- Issue
- 49
- ISSN
- 2470-9468 (ISSN-L)
- PMC
- PMC7402634
- OpenAlex
- W3042587425
- Cited by
- 723
- References
- 107
- Citations by year
- 2026: 15 · 2025: 27 · 2024: 63 · 2023: 101 · 2022: 182 · 2021: 251 · 2020: 83
- FWCI
- 20.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Science Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (HL137006, HL137915, AI144288, P30-CA016520, AI105343, AI115712, AI117950, AI108545, AI082630, CA210944, T32 CA009140.)
- National Institute of Allergy and Infectious Diseases (AI136660)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
- Keywords
- severe COVID-19, SARS-CoV-2, immune perturbation, hyperinflammation, T cell activation, innate lymphoid cells, granulocytes, neutrophil-to-lymphocyte ratio, prognostic factors, organ failure
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Aged, Female, Humans, Immunity, Innate, Immunologic Memory, Lymphocyte Activation, Male, Middle Aged, Neutrophils, Pneumonia, Viral, T-Lymphocytes, B-Lymphocyte Subsets, Cytokines, Coronavirus Infections, Lymphocyte Count, Pandemics, Clonal Selection, Antigen-Mediated
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.